EPISODE · Apr 29, 2026 · 13 MIN
Disease-Modifying Therapies
from Addressing Neurodevelopment, Qualify of Life and Emerging Therapies in Dravet Syndrome Patients · host Annenberg Center for Health Sciences
Antisense oligonucleotide– zorevunersenHistamine antagonist– clemizole hydrochlorideSerotonin agonist– bexicaserinGene therapy– ETX101
Embed this episode
NOW PLAYING
Disease-Modifying Therapies
0:00
13:24
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Addressing Neurodevelopment, Qualify of Life and Emerging Therapies in Dravet Syndrome Patients?
This episode is 13 minutes long.
When was this Addressing Neurodevelopment, Qualify of Life and Emerging Therapies in Dravet Syndrome Patients episode published?
This episode was published on April 29, 2026.
Can I download this Addressing Neurodevelopment, Qualify of Life and Emerging Therapies in Dravet Syndrome Patients episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!